logo

   Reniguard's R&D in Early Detection

Although the past two decades have seen remarkable advances in the development of oncological therapeutics and personalized cancer treatments, early detection/diagnosis remains the most effective way of saving lives.  Reniguard is developing mutation assays for the early detection and risk assessment of certain cancers.  Reniguard is also developing assays for the early diagnosis of drug-resistance during treatment of chronic hepatitis B.

Technical Innovations

Cancer is a genetic disease caused by mutations or a combination of mutations with epigenetic modifications.  These cancer-derived genetic materials, when detected from body fluids (blood, urine, etc), can provide useful information for cancer risk assessment, early diagnosis, post-surgery monitoring and prognosis purposes.  However, this requires the detection methods to be ultra-sensitive and preferably quantitative.  Body fluids contain normal non-mutated DNAs which suppress the detection of mutated DNAs.  As the amount of mutated DNAs is very little compared with the amount of normal DNAs at the early stage, detecting mutated DNAs is like finding "a needle in a haystack" .  Scientists at Reniguard have developed mutation detection technologies that have detection sensitivities as high as 0.1 - 0.001%.  This level of sensitivity makes early detection possible.  We also have strong expertise in other aspects of assay development that are crucial to early detection.

 


 

 

 

 

 

 

Publications & Presentations

Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Long After Achieving HBsAg Seroconversion: A Need for an Improved Hepatitis B Virus DNA Assay. Clin Microbial 2:127, 2013

Ultrasensitive Quantification of HBV Mutants and Potential Clinical Applications (Invited presentation), 14th International Symposium on Viral Hepatitis and liver Disease (ISVHLD), June 2012

Ultrasensitive Quantification of Complex DNA Mutations (Presentation), BIOMARKER WORLD CONGRESS 2012

Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion.  Journal of Hepatology. 56:795-802, 2012.

Quantification of complex precore mutations of hepatitis B virus by SimpleProbe real time PCR and dual melting analysis.  Journal of Clinical Virology. 51(4):234-240, 2011

Ultrasensitive quantification of hepatitis B virus A1762T/G1764A mutant by a SimpleProbe PCR using a wild-type-selective PCR blocker and a primer-blocker-probe partial-overlap approach.  Journal of Clinical Microbiology. 49(7):2440-2448, 2011

HBV Drug Resistance Development, Testing and Prevention.  Current Hepatitis Reports.  9:223-230, 2010

Rapid and sensitive detection of hepatitis B virus 1762T/1764A double mutation from hepatocellular carcinomas using LNA-mediated PCR clamping and hybridization probes. J Virol Methods. 158:24-29, 2009.

 
copy right © 2008-2014, Reniguard Life Sciences Inc, all rights reserved